ACSL4 and neoplasm: This synergy was robustly validated in a U2OS xenograft model, where the combination of (20S)-PPT and IKE achieved a superior 74% reduction in tumor volume compared to IKE monotherapy (42%), accompanied by confirmed upregulation of ACSL4 in tumor tissues.